interesting :)
MYMX has had a cold-chain-independent platform for vaccine development for a few years now. This may turn out to be an invaluable technology considering news from Pfizer and Moderna today (see right below - from Marketwatch). Below that is from a 2018 press release from MYMX describing results from their platform. In essence "cold-chain independent" means vaccine distribution almost everywhere under almost any temperature conditions. Today:The COVID-19 vaccine candidates being developed by Moderna Inc. and BioNTech and Pfizer Inc. will require stringent standards for refrigeration, and that may hamper how they are distributed to the hundreds of millions of Americans expecting to receive them.Executives from Moderna and Pfizer on Wednesday separately told the Centers for Disease Control and Prevention?s Advisory Committee on Immunization Practice on Wednesday that mRNA-1273, which is Moderna?s coronavirus vaccine candidate, requires a storage temperature of negative 4 degrees Fahrenheit. BioNTech and Pfizer?s candidates, BN1162b2 and BNT162b2, need to be stored in negative 94 degrees Fahrenheit.?These storage conditions would make traditional office or pharmacy administration very difficult,? SVB Leerink analysts wrote in a note to investors on Thursday. ?These conditions could be met at tertiary hospitals and laboratories and could be accommodated in intensive one-day vaccination events at such sites, but this would still only cover a fraction of the healthy population.?From 2018:November 2018 ? Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announces that new data is presented today by Mymetics at the annual Mucosal Vaccines, Adjuvants and Delivery meeting in Lausanne, Switzerland.Since 2015, Mymetics has been leading a consortium to develop thermostable and cold-chain independent virosome-based vaccines. The project, named MACIVIVA, is funded as part of Horizon 2020, the European Union research and innovation framework program and by the Swiss State Secretariat for Education, Research and Innovation (SERI), and has a total grant value of #$%$8.4 million. With the MACIVIVA project, Mymetics has brought together the leading contract manufacturers and the relevant expertise for spray drying, freeze drying and analytical techniques from the pharmaceutical industry.The late breaker presentation today, titled ?Thermostable Virosome-based Vaccines Under New Solid Dosage Forms? will be presented by Dr. Sylvain Fleury, Mymetics? CSO.Dr. Fleury will present data showing that Mymetics? HIV virosome-based candidate vaccine was successfully transformed into dry powder and into sub lingual tablets. These new solid dosage forms were stored at 1 to 3 month time intervals at 4?C (40?F), 25?C (77?F) and 40?C (104?F) and the vaccine candidate maintained its structural integrity, while the liquid formulation showed structural degradation at 25?C (77?F) and 40?C (104?F). In pre-clinical in vivo studies the nasal delivery of spray dried virosomes and oral delivery of the sublingual tablet showed to be a possible effective, needle-free route for immunization, triggering immune responses in not only the serum, but also in the mucosal immune compartments.
